Welcome to our dedicated page for Adc Therapeutics Sa news (Ticker: ADCT), a resource for investors and traders seeking the latest updates and insights on Adc Therapeutics Sa stock.
ADC Therapeutics SA reports news on its commercial-stage oncology business focused on antibody-drug conjugates. The company markets ZYNLONTA (loncastuximab tesirine-lpyl), a CD19-directed ADC with FDA accelerated approval and European Commission conditional approval for relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy.
Recurring updates cover ZYNLONTA product revenue, manufacturing and commercialization activity, clinical development in combination regimens and earlier lines of therapy, including LOTIS program studies, and corporate financing matters. Company news also includes quarterly financial results, investor presentations, conference participation and equity inducement grants under its compensation plans.
ADC Therapeutics (NYSE: ADCT) reported Q2 2026 net product revenue of $18.6 million (vs. $18.1 million in Q2 2025) and net loss of $16.6 million (vs. $56.6 million). License revenue was $0.6 million. Total operating expenses fell 29% to $44.7 million, driven mainly by lower R&D.
The company completed enrollment of the 100-patient LOTIS-7 trial of ZYNLONTA plus glofitamab and plans Breakthrough Therapy designation submissions. After an FDA pre-sBLA meeting raised benefit-risk concerns about the LOTIS-5 confirmatory trial, ADC Therapeutics is reassessing the regulatory path. Cash and equivalents were $219.1 million, with an expected runway at least into 2028. A strategic reorganization, including a 17% workforce reduction, is expected to deliver about $10 million in annualized cost savings.
ADC Therapeutics (NYSE: ADCT) will host a conference call and live webcast on Thursday, August 13, 2026, at 8:30 a.m. EDT to report its second quarter 2026 financial results and provide operational updates.
Investors can access the call via registration and toll-free dial-in 1-800-836-8184 (North America/Canada) or through a live webcast under “Events and Presentations” in the Investors section at ir.adctherapeutics.com. An archived webcast will remain available for 30 days following the event.
ADC Therapeutics (NYSE: ADCT) granted stock options to purchase 17,000 common shares to a new employee on July 1, 2026 as a material employment inducement. The award was approved under the company’s Inducement Plan and relies on NYSE Rule 303A.08.
The options vest 25% on the first anniversary and 1/48th monthly thereafter, fully vesting on the fourth anniversary, subject to continued employment.
ADC Therapeutics (NYSE: ADCT) completed enrollment in the LOTIS-7 Phase 1b trial of ZYNLONTA plus glofitamab in relapsed or refractory DLBCL. The study includes 100 patients at a 150 µg/kg ZYNLONTA dose across 30 sites, with full data expected in Q4 2026.
ADC Therapeutics (NYSE:ADCT) announced a strategic reorganization focused on advancing the ZYNLONTA franchise, including LOTIS-5 and LOTIS-7 trials. The plan includes an estimated 17% workforce reduction, expected annualized savings of about $10 million, one-time charges of roughly $3 million, and an expected cash runway into 2028.
ADC Therapeutics (NYSE: ADCT) reported topline Phase 3 LOTIS-5 results for ZYNLONTA + rituximab in relapsed or refractory DLBCL. The combo met the primary endpoint, improving progression-free survival (HR=0.73; p=0.008) vs R-GemOx, with higher response and complete response rates and longer complete response duration.
Overall survival showed no detrimental effect (HR=0.96). Total adverse event rates were similar between arms, but serious, Grade 5 events and withdrawals were more frequent with ZYNLONTA + rituximab, especially in patients ≥75. ADC Therapeutics plans a pre-sBLA FDA meeting in August and targets an sBLA filing in Q4 2026.
ADC Therapeutics (NYSE: ADCT) reported Q1 2026 results and provided clinical updates. Q1 net product revenue was $20.0M; net loss was $33.0M ($0.21/share) and adjusted net loss was $19.7M ($0.13/share). Cash and cash equivalents totaled $231.0M with a runway at least into 2028. Key clinical catalysts: LOTIS-5 topline expected in 2Q 2026 and full LOTIS-5 and LOTIS-7 data anticipated by year-end.
ADC Therapeutics (NYSE: ADCT) granted options to purchase an aggregate of 49,400 common shares to two new employees on May 1, 2026 as material inducements under its Inducement Plan.
The Compensation Committee approved the grants, made under the NYSE employment inducement exemption (Rule 303A.08). Vesting is 25% at the first anniversary, then 1/48th monthly thereafter, with full vesting at the fourth anniversary subject to continued employment.
ADC Therapeutics (NYSE: ADCT) will host a conference call and live webcast on Monday, May 4, 2026 at 8:30 a.m. EDT to report first-quarter 2026 financial results and provide operational updates. Participants are asked to register; a North America toll-free dial-in is provided and the webcast will be archived for 30 days.
ADC Therapeutics (NYSE: ADCT) granted an inducement equity award of 17,000 options to a new employee on April 1, 2026. The award was approved by the Compensation Committee under the company's Inducement Plan and relies on the NYSE employment inducement exemption Rule 303A.08.
The options vest 25% after one year and then 1/48th monthly, fully vesting after four years, subject to continued employment.